GENENTA SCIENCE SPA

DelveInsight's 'Glioblastoma Pipeline Insight, 2024' report details 190+ companies developing 200+ therapies, including Enzastaurin, Marizomib, VT1021, and ONC201, with insights on mechanism of action, route of administration, and market dynamics.

DelveInsight's 'Hematopoietic Stem Cell Transplantation Pipeline Insight, 2024' report details 20+ companies developing therapies, including Orchard Therapeutics, Lisata Therapeutics, Genenta science, and Editas Medicine. Key therapies in clinical trials are OTL-204, OTL-105, LSTA201, Temferon, and EDIT-301. The report covers mechanism of action, route of administration, and market dynamics.

Genenta Science to host a webinar on 'Immuno Gene & Cell Therapy for the Treatment of Solid Tumors' on April 28, 2022 at 8:00 AM EDT / 2:00 PM CET.

Italy's Ambassador to the US, Mariangela Zappia, presented the interim report on the Internationalisation of Biotechnology Industries at the US Senate, highlighting potential for increased investment between Italy and the US in biotechnology. The report, presented by Mauro Battocchi and Pierluigi Paracchi, outlines strategies to enhance the competitiveness of Italy's biotech sector, focusing on venture capital support for R&D activities. The meeting aimed to showcase Italy's biotech excellence to US investors and included representatives from leading pharmaceutical and biotech companies, NIH researchers, and FDA officials.

Genenta Science's CEO, Pierluigi Paracchi, to speak at 'Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective' on Oct 25 at U.S. Senate, organized by NSCEB and Italian Embassy in the U.S.

Genenta Science's CEO, Pierluigi Paracchi, to speak at 'Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective' on Oct 25, 2024, in Washington, D.C., discussing biotech sector internationalization and strategic investments.

Genenta Science's CEO, Pierluigi Paracchi, to speak at the Italy-U.S. meeting on biotechnology strategies on October 25, 2024, in Washington, D.C., discussing the importance of international collaboration and investment in biotech.

Genenta Science announces AIFA approval for a Phase 1 trial of Temferon™ in metastatic Renal Cell Cancer (mRCC), expanding its potential applications. The trial aims to offer a new treatment option for late-stage mRCC patients with no current options, leveraging insights from previous Glioblastoma Multiforme (GBM) studies. Preclinical studies show synergy between Temferon and other immunotherapies, potentially improving outcomes for solid tumor patients.